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ABSTRACT
 
Thalassaemia caused by defects in the synthesis of the 
haemoglobinchains. Mainly two types of thalassaemia 
are found in Chattogram, Bangladesh. Alpha 
thalassemia is caused by reduced or absent synthesis of 
alpha globin chains, and beta thalassemia is caused by 
reduced or absent synthesis of beta globin chains. The 
symptoms of thalassemia can vary. Some of the most 
common ones include: Bone deformities, darkurine, 
delayedgrowh and development excessive tiredness 
and pale skin and sometimes fever. Not everyone has 
visible symptoms of thalassemia. Signs of the disorder 
also tend to show up later in childhood or adolescence. 
We found 55% female patients and 45% male patients 
of thalassaemia.45% child (4-11 year), 18% infant 63% 
patients are different ages. Treatment process in 
Chattogram: 95% patient take blood transfusion as 
treatment and 5%patients take some medicine such as 
hexosamine. 90% patients are satisfied with treatment 
of thalassaemia. Maximum (95%) patients are the 
patients of beta thalassaemia. Finally, it can be stated 
that further analysis of these data will be helpful in 
future progression of efficient treatment planning, 
medical services, awareness rising and also in further 
research on different aspects of thalassaemia patients 
and treatment. 
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INTRODUCTION 
Thalassemia is a blood disorder passed 
down through families (inherited) in which 
the body makes an abnormal form or 
inadequate amount of hemoglobin. 
Hemoglobin is the protein in red blood 
cells that carries oxygen. The disorder 
results in large numbers of red blood cells 
being destroyed, which leads to anemia 
[1]. This are a group of inherited 
microcytic, hemolytic anemias 
characterized by defective hemoglobin 
synthesis. Beta-thalassemia is more 
common among people of Mediterranean, 
Middle Eastern, Southeast Asian, or Indian 
ancestry. Symptoms and signs result from 
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anemia, hemolysis, splenomegaly, bone 
marrow hyperplasia, and, if there have 
been multiple transfusions, iron overload 
[2]. Diagnosis is based on genetic tests and 
quantitative hemoglobin analysis. 
Treatment for severe forms may include 
transfusion, splenectomy, chelation, and 
stem cell transplantation [3]. Thalassemia 
is a very complicated disorder; the more 
that you, as a patient or caregiver, know 
about thalassemia and its treatment, the 
better you will be able to meet its 
challenges and to know what to do to live 
a healthier, fuller life. We think that this 
Guide will help you achieve that goal [4]. 
Thalassemia a blood disorder, that means 
passed from parents to children through 
genes, and also actually caused when the 
body doesn’t make enough of a protein 
called hemoglobin, an important part of 
red blood cells etc. [5]. Moreover, there 
isn’t enough hemoglobin, the body’s red 
blood cells don’t function appropriately 
and they last shorter periods of time, that 
means there are fewer healthy red blood 
cells traveling in the bloodstream 
eventually [6]. Moreover, red blood cells 
also carry oxygen to all the cells of the 
body. Oxygen is a kind of food that cells 
use to function [7]. So, when there are not 
enough well red blood cells, there is also 
not sufficient oxygen delivered to all the 
other cells of the body, which may reason 
a person to feel tired, weak or short of 
breath [8]. This is a situation called 
anemia. People with thalassemia may have 
mild or Spartan anemia. Spartan anemia 
can harm organs and lead to death [9]. 
 
Methodology 
This cross sectional study with a self-
administered survey was conducted during 
July to October 2019 in Chittagong, 
Bangladesh. 
 Interviewing 120 patients of 
thalassaemia 
 Participants were recruited based on 
the following inclusion criteria:  
 Undergraduate study 
 Aged 0 to 56 years 
 Permanent residents of Bangladesh.  
 Living in Chittagong division, 
Bangladesh. 
 
RESULTS AND DISCUSSION 
A total of 120 patients were included in 
this study, in part one 55% patients are 
male and 40% are female. On the other 
hand 90% patient’s symptoms are fatigue, 
70% weakness, 50% distaste, 15% 
abdominal swelling and 7% dark urine. 
55% patients are child and 45% are adult. 
6% patients are middle classes, 30% 
higher class and 10% are lower class. 95% 
patients take blood transfusion as 
treatment and 5% takes medicine. 90% 
patients are satisfied with treatment and 
10% are not satisfied. 
 
PERCENTAGE OF PATIENTS GENDER 
 
Figure 1: Percentage of patient’s gender. 
Parcentage 
female
male
  
12 Page 10-15 © MAT Journals. All Rights Reserved 
 
Journal of Advances in Pharmacy Practices  
Volume 2, Issue 1 
 
We can observe that in the Chittagong 
division, Bangladesh the thalassemia 
patients are 55% female & another 45% 
patients are male. 
 
Graphical Representation of Symptoms 
 
Figure 2: Graphical representation of symptoms. 
 
Table 1: Symptoms of Thalassaemia. 
Weakness Fatigue Distaste Fever Dark urine Abdominal swelling 
70% 90% 50% 10% 7% 15% 
 
In research, we found 90% patients 
symptoms were fatigue, 70% weakness, 
50% distaste, 10% fever, 7% dark urine 
and 15% abdominal swelling among 120 
patients of thalassaemia around 
Chittagong.
 
Table 2: Patients, gender and age. 
Categories Number of person 
Age Range 
(year) 
Male 
Patient 
Female 
Patient 
Infant 20 0-3 2.2% 1.00% 
Child 55 4-11 55% 45% 
Adolescent 15 12-20 3% 4% 
Early Adult 10 21-34 11% 13% 
Midlife 
Adult 
15 35-49 15% 40% 
Late Adult 05 50 Above 40% 30% 
From the table, we found number of 
patients of thalassaemia according to 
infant, child, adolescent, early adult, 
midlife adult, late adult 20, 55, 15, 10, 
05 and their percentage male & female, 
2.25% & 1.00%, 55% & 45%, 3% & 
4%, 11% & 13%, 15% & 40%, 40% & 
30%.
 
Table 3: Patients financial condition. 
Condition Higher class Middle class Lower class 
Percentage 60% 30% 10% 
 
0%
50%
100%
  
10 Page 10-15 © MAT Journals. All Rights Reserved 
 
Journal of Advances in Pharmacy Practices  
Volume 2, Issue 1 
 
From the research, we found total financial 
condition of thalassemia patients in 
Chottogram that are given in the table and 
graph. About 60 % patients are higher 
class and 30% patients are middle class 
and 10% are lower class.
 
 
Figure 3: Satisfaction rate on treatment and service. 
 
In our survey, we found among all the 
patients and their families in Chittagong 
90% patients are satisfied with the 
treatment & 10% patients are not satisfied 
with the treatment facilities here in 
Chottogram.
 
 
Figure 4: Treatment process. 
 
In Chottogram, division we found the 
treatment process such as blood 
transfusion and medicine as hexosamine 
and sometimes chelation therapy. Among 
all the patients 95% are treated with blood 
transfusion and 5% patients take medicine 
and therapy as their treatment of 
thalassaemia.
 
Blood
transfution
Medicine
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Figure 5: Types of thalassaemia. 
 
Out of 120 patients of thalassemia around 
the Chottogram, we found 95% people are 
the patients of beta thalassaemia and 5% 
are the patients of alpa thalassaemia.
 
Table 4: Age range of patients. 
Categories Age Range(year) Percentage 
Infant 0-3 30% 
Child 4-11 50% 
Adolescent 12-20 8% 
Early Adult 21-34 5% 
Midlife Adult 35-49 5% 
Late Adult 50 Above 2% 
 
In our research, we found six categories of 
the patients and these are infant, child, 
adolescent, early adult, midlife adult & 
late adult and their percentage are 
according to 30%, 50%, 8%, 5%, 5% and 
2%. It can state that maximum patients of 
thalassaemia are child and that is not good 
news for the society. 
 
CONCLUSION 
Conclusion is the determination 
established by investigating in various 
ways and deducting by means of various 
reasons. So, based on the study sample 
after completion of the study, following 
conclusions can be drawn. On comparing 
from the results, significant difference 
between the alpa and beta thalassaemia 
shown. Maximum are the patients of beta 
thalassaemia. Therapy is not a known 
treatment of the thalassaemia in 
Chottogram division. In conclusion, this 
study talks about the testing, diagnosis and 
treatment of Thalassaemia. It can be stated 
that further analysis of these data will be 
helpful in future progression of efficient 
treatment planning, medical services, 
awareness raising and also in further 
research on different aspects of 
thalassaemia patients and treatment. 
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